This article is more than 5 years old. Information may no longer be current.

Carl Zeiss Meditec to collaborate with Oraya Therapeutics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Carl Zeiss Meditec has agreed to collaborate with Oraya Therapeutics and invest in the company’s low-energy radiotherapy treatment for wet age-related macular degeneration, according to a Carl Zeiss Meditec press release.

Under the collaboration agreement, Carl Zeiss Meditec will finance the implementation of Oraya’s growth strategy for up to 2 years and receive rights to participate in the company, reaching up to a majority stake after 2 years, the release said.

The funding amount was not disclosed.